nystatin-a1 and Pharyngeal-Neoplasms

nystatin-a1 has been researched along with Pharyngeal-Neoplasms* in 3 studies

Other Studies

3 other study(ies) available for nystatin-a1 and Pharyngeal-Neoplasms

ArticleYear
Candidal abscess in a second primary neoplasm of the neopharynx.
    The Journal of laryngology and otology, 2000, Volume: 114, Issue:12

    A candidal abscess is a known complication of disseminated candidiasis, particularly in immunocompromised patients. We report a second primary growth in the neopharynx brought to light by a candidal abscess in a non-immunocompromised patient.

    Topics: Antifungal Agents; Candidiasis; Carcinoma, Squamous Cell; Fluconazole; Humans; Male; Middle Aged; Neoplasms, Second Primary; Nystatin; Pharyngeal Neoplasms; Retropharyngeal Abscess; Treatment Outcome

2000
Can prophylactic application of immunoglobulin decrease radiotherapy-induced oral mucositis?
    American journal of clinical oncology, 1997, Volume: 20, Issue:4

    Therapeutic application of immunoglobulin is reported to be successful in radiation-induced oral and oropharyngeal mucositis. In this study the efficacy of prophylactic application of immunoglobulin was investigated. In 42 patients with head and neck cancer, postoperative radiation treatment or radiation combined with chemotherapy was performed. In 20 consecutive patients, prophylactic mucositis treatment consisted of panthenol (4 x 10 ml/day) and nystatin (4 x 1 ml/day). The 22 following patients received, supplementary to panthenol and nystatin, 800 mg (5 ml) human immunoglobulin intramuscularly once weekly. During the treatment time, the degree of mucositis was examined 3 times a week. The distribution of maximal mucositis degree revealed slightly more severe mucous membrane reaction in the control group compared with the immunoglobulin group (n.s.). The analysis of mean mucositis degrees in both groups demonstrated statistically significant differences (t test, p = 0.031) related to the entire group (n = 42) and to those 16 patients receiving radiation combined with chemotherapy. There was no significant immunoglobulin-induced effect on mucositis in patients treated by radiation alone. The time from the beginning of therapy to the first interruption could be prolonged 5 days in the immunoglobulin group (n.s.). In conclusion, it is demonstrated that the prophylactic application of immunoglobulin seems to lower the degree of radiation-induced mucositis. In comparison to the published data about therapeutically given immunoglobulin, the clinical efficacy of the prophylactic application of immunoglobulin as it is performed in this study is less evident.

    Topics: Adult; Aged; Anti-Bacterial Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Immunization, Passive; Immunoglobulins; Injections, Intramuscular; Laryngeal Neoplasms; Male; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Mouthwashes; Nystatin; Oropharynx; Pantothenic Acid; Pharyngeal Neoplasms; Pharyngitis; Radiation Injuries; Radiotherapy; Stomatitis

1997
[Esophageal mycoses after irradiation for cancers of the O.R.L. region. 3 cases].
    Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris, 1969, Volume: 86, Issue:9

    Topics: Anti-Bacterial Agents; Antineoplastic Agents; Candidiasis; Cobalt Isotopes; Esophageal Diseases; Esophagitis; Esophagoscopy; Glucocorticoids; Humans; Lip Neoplasms; Male; Middle Aged; Nystatin; Pharyngeal Neoplasms; Radiotherapy; Tonsillar Neoplasms

1969